GlucoTrack (GCTK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GCTK SEC filings page.
This page shows GlucoTrack, Inc. (GCTK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
GlucoTrack’s reported figures describe a research-led business funded largely through financing rather than operating cash generation.
Cash conversion is consistent with development spending: in FY2025, operating cash flow was an outflow of$15.2M against a net loss of$19.4M , while free cash flow was an outflow of$15.3M . Because capital expenditures were only$96K , most cash use came from ongoing operations rather than heavy physical investment.
Research and development reached
The balance sheet is being reshaped by financing: FY2025 financing cash flow was
Financial Health Signals
GlucoTrack, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
GlucoTrack, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
GlucoTrack, Inc. reported a net loss of $19.4M while operations used $15.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
GlucoTrack, Inc.'s EBITDA was -$3.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
GlucoTrack, Inc. reported a net loss of $3.8M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
GlucoTrack, Inc. held $1.1M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
GlucoTrack, Inc. invested $2.0M in research and development in Q2 2026. This represents a decrease of 36.0% from the same quarter a year earlier. Against the prior quarter it is down 5.4%.
Not reported for Q2 2026.
Not reported for Q2 2026.
GCTK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.0M-36.0% | $2.1M+13.9% | N/A | $3.2M+53.4% | $3.1M | $1.9M-12.9% | N/A | $2.1M+21.9% |
| SG&A Expenses | $1.4M-24.3% | $2.1M+18.0% | N/A | $1.1M-3.7% | $1.8M+102.7% | $1.8M+118.6% | N/A | $1.2M+123.7% |
| Operating Income | -$3.4Mn/m | -$4.2Mn/m | N/A | -$4.3Mn/m | -$4.8M | -$3.5Mn/m | N/A | -$3.3Mn/m |
| EBITDA | -$3.4M | -$4.2Mn/m | N/A | N/A | N/A | -$3.5Mn/m | N/A | -$3.2Mn/m |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $5K |
| Net Income | -$3.8Mn/m | -$4.3Mn/m | N/A | -$4.2M | -$4.8M | -$6.8Mn/m | N/A | N/A |
| EPS (Basic) | $0.76 | $2.65 | $1.13 | $4.64 | $9.62 | $40.14n/m | $1238.00+187475.8% | $1.09 |
| EPS (Diluted) | $0.76 | $2.65 | $1.13 | $4.64 | $9.62 | $40.14n/m | $1238.00+187475.8% | $1092.00 |
| Diluted Shares (Avg) | 5M | 2M | N/A | 899,410 | 494,504 | 169,345-32.2% | N/A | 4,663 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
GCTK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5M-85.4% | $4.4M-54.7% | $7.8M+32.1% | $8.3M+903.6% | $10.2M+1579.3% | $9.6M+356.4% | $5.9M+20.9% | $826K-88.5% |
| Current Assets | $1.4M-86.3% | $4.2M-55.4% | $7.7M+32.9% | $8.1M+1162.6% | $10.1M+2179.9% | $9.5M+388.1% | $5.8M+18.5% | $642K-91.0% |
| Cash & Equivalents | $1.1M-88.2% | $3.9M-56.8% | $7.4M+31.4% | $7.9M+2174.3% | $9.6M+5909.4% | $9.1M+507.9% | $5.6M+25.0% | $346K-95.0% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.2M-2.8% | $5.2M+121.2% | $5.0M-73.5% | $5.5M+14.3% | $3.3M-14.5% | $2.4M+36.1% | $18.9M+1008.4% | $4.8M+196.0% |
| Current Liabilities | $3.0M-3.1% | $5.0M+155.1% | $4.8M+274.4% | $5.3M+14.9% | $3.1M-15.7% | $1.9M+31.6% | $1.3M-15.7% | $4.6M+217.1% |
| Non-Current Liabilities | $248K+1.2% | $232K-42.6% | $237K-98.7% | $242K+2.1% | $245K+3.4% | $404K+62.9% | $17.7M+8908.7% | $237K+28.8% |
| Total Equity | -$1.7M-125.3% | -$851K-111.7% | $2.8Mn/m | $2.8Mn/m | $6.9Mn/m | $7.3M+1836.8% | -$13.0M-506.6% | -$4.0M-172.4% |
| Retained Earnings | -$160.0Mn/m | -$156.2Mn/m | -$151.8Mn/m | -$148.2Mn/m | -$144.0Mn/m | -$139.3Mn/m | -$132.4Mn/m | -$122.4Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GCTK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.6Mn/m | -$4.0Mn/m | -$3.9Mn/m | -$4.6M | -$3.7Mn/m | -$2.9Mn/m | -$3.5Mn/m | N/A |
| Depreciation & Amortization | $21K | $22K+175.0% | N/A | N/A | N/A | $8K+100.0% | N/A | $10K-28.6% |
| Stock-Based Compensation | N/A | $61K+52.5% | N/A | N/A | N/A | $40K+81.8% | N/A | N/A |
| Capital Expenditures | N/A | N/A | $20Kn/m | $67K+103.0% | $0-100.0% | $9K-84.7% | $0 | $33K |
| Free Cash Flow | N/A | N/A | -$4.0Mn/m | -$4.7M | -$3.7Mn/m | -$2.9Mn/m | -$3.5M | N/A |
| Investing Cash Flow | N/A | N/A | -$20Kn/m | -$67Kn/m | $0n/m | -$9Kn/m | $0 | -$33K |
| Financing Cash Flow | $803K-80.7% | $591K-90.8% | $3.5M-60.2% | $3.0M | $4.2M | $6.4M | $8.8Mn/m | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
GCTK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | -151.6% | -69.1% | -94.1%+686.4pp | N/A | N/A |
| Return on Assets | -255.1%-208.5pp | -99.5%-28.4pp | N/A | -50.3% | -46.6% | -71.1%+67.9pp | N/A | N/A |
| Current Ratio | 0.46-2.8x | 0.85-4.0x | 1.61-2.9x | 1.53+1.4x | 3.27+3.1x | 4.85+3.5x | 4.52+1.3x | 0.14-4.8x |
| Liabilities-to-Equity | N/A | N/A | 1.77 | 2.01 | 0.48 | 0.32-4.3x | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GlucoTrack, Inc. GCTK | FY2025 | N/A | -$19.4M | N/A | $1.9M | — |
| Femasys Inc. FEMY | FY2025 | $2.3M | -$18.6M | N/A | $11.8M | 43/100 |
| Innovative Eyewear, Inc. LUCY | FY2025 | $2.7M | -$7.6M | N/A | $6.9M | 58/100 |
| Harvard Bioscience Inc HBIO | FY2025 | $86.5M | -$56.7M | -65.5% | $37.9M | 46/100 |
Where GlucoTrack, Inc. Ranks
Frequently Asked Questions
Is GlucoTrack, Inc. profitable?
No, GlucoTrack, Inc. (GCTK) reported a net loss of $19.4M in fiscal year 2025.
What is GlucoTrack, Inc.'s EBITDA?
GlucoTrack, Inc. (GCTK) had EBITDA of -$16.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is GlucoTrack, Inc.'s return on equity (ROE)?
GlucoTrack, Inc. (GCTK) has a return on equity of -685.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GlucoTrack, Inc.'s free cash flow?
GlucoTrack, Inc. (GCTK) recorded an outflow of $15.3M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GlucoTrack, Inc.'s operating cash flow?
GlucoTrack, Inc. (GCTK) recorded an outflow of $15.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are GlucoTrack, Inc.'s total assets?
GlucoTrack, Inc. (GCTK) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are GlucoTrack, Inc.'s capital expenditures?
GlucoTrack, Inc. (GCTK) invested $96K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GlucoTrack, Inc. spend on research and development?
GlucoTrack, Inc. (GCTK) invested $9.8M in research and development during fiscal year 2025.
What is GlucoTrack, Inc.'s current ratio?
GlucoTrack, Inc. (GCTK) had a current ratio of 1.61 as of fiscal year 2025, which is generally considered healthy.
What is GlucoTrack, Inc.'s liabilities-to-equity ratio?
GlucoTrack, Inc. (GCTK) had a liabilities-to-equity ratio of 1.77 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is GlucoTrack, Inc.'s return on assets (ROA)?
GlucoTrack, Inc. (GCTK) had a return on assets of -247.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GlucoTrack, Inc.'s P/E ratio?
GlucoTrack, Inc. (GCTK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.9M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GlucoTrack, Inc.'s price-to-sales ratio?
GlucoTrack, Inc. (GCTK) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.9M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does GlucoTrack, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, GlucoTrack, Inc. (GCTK) held $7.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.2M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is GlucoTrack, Inc.'s Piotroski F-Score?
GlucoTrack, Inc. (GCTK) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GlucoTrack, Inc.'s earnings high quality?
GlucoTrack, Inc. (GCTK) reported a net loss of $19.4M while operations used $15.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.